Babak Orandi (US)

Invited Speaker

Associate Professor · Department of Surgery · New York University Grossman School of Medicine · New York

Babak Orandi
Biography Click to expand

Babak Orandi is an abdominal transplant surgeon, obesity medicine specialist, and NIH-funded investigator at NYU Langone, where he is an Associate Professor of Surgery and Medicine and also the founding director of the PeriOperative Weight Evaluation and Reduction (POWER) Clinic, which is focused on helping patients lose weight to facilitate solid organ transplant and living donation. He completed a combined Bachelors/MD program at the University of Michigan, where he graduated with distinction in research and completed a master’s in clinical investigation. He did his general surgery residency and PhD in clinical investigation at Johns Hopkins, followed by an abdominal transplant surgery fellowship at the University of California, San Francisco. He also completed an obesity medicine fellowship at Weill Cornell. He has published >140 peer-reviewed papers, including in the New England Journal of Medicine, JAMA, BMJ, and the Annals of Internal Medicine.

Obesity Management in Transplantation: Current Evidence and Practical Approaches Click to watch
Babak Orandi (Guest Speaker)
In this episode of Behind the Paper, Macey Levan, Social Media Editor for the Transplantation journals, speaks with Babak J. Orandi, MD, about the article. Babak J. Orandi will be presenting this work at TTS 2026.

Antiobesity Interventions in Living Organ Donor Candidates: Ethical and Policy Considerations

The discussion focuses on the ethical and policy questions raised by antiobesity interventions for living organ donor candidates. Dr. Orandi explains how obesity can affect donor eligibility and why weight management should be approached as long-term care rather than simply meeting a temporary BMI threshold to enable donation.

The episode explores the four major principles of bioethics — autonomy, beneficence, non-maleficence, and justice — and how they apply to living donor evaluation. Dr. Orandi also discusses the growing role of GLP-1 medications, access to treatment, donor safety, and legal and ethical concerns related to funding weight-loss interventions before donation.

The conversation highlights the importance of sustainable obesity management, better long-term follow-up data, and updated guidance from transplant societies as antiobesity therapies become more widely used.

Programme roles

Monday, September 21, 2026

Room C3.3
Presenter Abstract Session Kidney
Metabolic health and kidney transplant outcomes
Lecture Metabolic bariatric surgery vs GLP-1 receptor agonists in dialysis patients with diabetes and obesity: a target trial emulation study

Tuesday, September 22, 2026